© Copyright - Newspaper WordPress Theme by TagDiv
Febuxostat
Also known as / Synonyms: Febuxostat, Non-Purine Xanthine Oxidase Inhibitor, Antigout
Potent non-purine xanthine oxidase inhibitor tablet that lowers uric acid levels and dissolves painful gout crystals.
Clinical Snapshot & Specifications
Approved Indications & Medical Uses
- Chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom allopurinol is not clinically advisable.
- Prevention of recurrent acute gout flares and reduction/dissolution of tophaceous gout deposits.
- Hyperuricemia associated with tumor lysis syndrome in patients undergoing hematological chemotherapy.
Contraindications (Do Not Use If…)
- Concomitant use with azathioprine or 6-mercaptopurine (severe, life-threatening bone marrow toxicity).
- Known hypersensitivity to febuxostat or formulation components.
- Treatment of asymptomatic hyperuricemia (not recommended without clinical gout or tophi).
Important Clinical Precautions & Warnings
- Cardiovascular risk: postmarketing cardiovascular safety trials (CARES trial) showed higher rates of cardiovascular death with febuxostat compared to allopurinol; assess cardiovascular risk before prescribing.
- Gout flare prophylaxis required: an increase in acute gout flares frequently occurs during initiation due to rapid mobilization of urate from tissue deposits; co-prescribe NSAIDs or colchicine prophylaxis for at least the first 6 months.
- Hepatic effects: postmarketing reports of serious hepatic failure; obtain baseline liver function tests and periodically monitor transaminases.
- Severe skin reactions: Stevens-Johnson syndrome and DRESS syndrome reported; discontinue immediately if progressive skin rash develops.
- No dose adjustment in mild-to-moderate renal impairment: unlike allopurinol, febuxostat is eliminated equally via hepatic and renal pathways; safe in renal impairment (eGFR 30-89 mL/min).
Special Populations (Paediatric & Geriatric Care)
Pediatric: Safety and efficacy have not been established in patients under 18 years. Geriatric: Safe and effective; no dose adjustment needed based on age alone.
Side Effects & Adverse Reactions
Common Side Effects (Usually Mild)
Liver function abnormalities (elevated transaminases), nausea, arthralgia, acute gout flares (initial), diarrhea, and skin rash.
Serious Side Effects — Seek Urgent Medical Care
Cardiovascular thromboembolic death, acute hepatic failure, Stevens-Johnson syndrome, toxic epidermal necrolysis, and severe hypersensitivity angioedema.
Action: Discontinue medication and seek immediate medical attention or call emergency services if any serious symptom occurs.
Drug, Food & Substance Interactions
- Azathioprine and 6-mercaptopurine: STRICTLY CONTRAINDICATED; xanthine oxidase inhibition prevents metabolism of these thiopurines, causing fatal pancytopenia.
- Theophylline: may increase theophylline plasma concentrations; monitor levels.
- No clinically significant interactions with colchicine, naproxen, indomethacin, or antacids.
Pregnancy & Lactation Clinical Safety
Pregnancy Safety:
Use with caution — see notesThere are no adequate and well-controlled studies in pregnant women. Animal reproduction studies did not show teratogenic effects at therapeutic doses. Gout is uncommon in women of childbearing age; use only if clearly needed.
Lactation & Breastfeeding:
Use with caution — see notesFebuxostat is excreted in animal milk; presence in human breast milk is unknown. Exercise caution when administering to nursing mothers.
Storage, Administration & Overdose Protocol
🌡️ Recommended Storage:
Store tablets at 20°C to 25°C (68°F to 77°F). Protect from light and moisture.
⏱️ Missed Dose Protocol:
Take the missed dose as soon as remembered on that day. If close to the next scheduled dose, skip and resume regular schedule. Do not take a double dose.
No specific antidote exists. In clinical studies, doses up to 300 mg/day for 7 days were evaluated without significant toxicity. Provide standard supportive gastric lavage and symptomatic monitoring.
